Combined MEK and YAP inhibition in a mouse model of neuroblastoma: A promising approach for minimal residual disease

In brief

This study investigates combined MEK and YAP inhibition as a strategy to overcome resistance in high-risk neuroblastoma treatment. Using a mouse model mimicking post-surgical minimal residual disease, researchers address the challenge of YAP-mediated resistance that develops during long-term trametinib therapy.

• Trametinib (MEK inhibitor) shows efficacy in neuroblastoma models and prolongs survival in minimal residual disease settings.
• Long-term trametinib monotherapy leads to resistance via YAP activation in the Hippo pathway.
• Combined MEK and YAP inhibition may overcome resistance mechanisms in high-risk neuroblastoma treatment.
• Minimal residual disease mouse models effectively mimic post-surgical residual tumor for therapy testing.

Written by the GCMD Library team from the article.